Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.

Simeon I TaylorHua-Ren CherngZhinous Shahidzadeh YazdiMay E MontasserHilary B WhitlatchBraxton D MitchellAlan R ShuldinerElizabeth A StreetenAmber L Beitelshees

Published in: medRxiv : the preprint server for health sciences (2023)

Research grants from the National Institute of Diabetes and Digestive and Kidney Diseases: R21DK105401, R01DK108942, T32DK098107, and P30DK072488.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
skeletal muscle
adipose tissue
insulin resistance